RxDoctor Payments Data

Jill Smith, MD

Ophthalmology · Newton, MANPI 1962598011

Payments from drug & device makers

$3,220in general payments, 2019–2025

Across 129 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$873
  • Oyster Point Pharma, Inc.$529
  • Alcon$488
  • Sun Pharmaceutical Industries Inc.$378
  • Tarsus Pharmaceuticals, Inc.$265
  • Dompe US, Inc.$174
  • plus $514 from 9 others

What the payments were for

  • Food & beverage$3,15698%
  • Gifts$642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,220 in reported general payments places this provider in the 70th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$415,482
Medicare patients
1,355
Services billed
3,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine51$49,768
TyrvayaVarenicline Tartrate48$38,235
LumiganBimatoprost63$31,221
XiidraLifitegrast32$27,298
RhopressaNetarsudil Mesylate43$21,842
RocklatanNetarsudil Mesylat/Latanoprost29$21,545
Timolol Maleate323$19,598
CombiganBrimonidine Tartrate/Timolol37$18,915
Restasis MultidoseCyclosporine17$18,452
Alphagan PBrimonidine Tartrate23$12,848
Prednisolone Acetate295$9,302
Latanoprost586$7,240
Loteprednol Etabonate13$6,217
ZioptanTafluprost/Pf12$6,076
VyzultaLatanoprostene Bunod11$5,955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Restasis Multidose, Alphagan P$873$131,204191 claims
Oyster Point Pharma, Inc.Tyrvaya$529$38,23548 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$148$33,25343 claims
AlconSimbrinza$488$5,50622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Newton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →